Editas Medicine (EDIT) PT Raised to $40 at BMO Capital
Tweet
Share
E-mailGet Alerts EDIT Hot Sheet
Price: $2.82 +0.36%
Rating Summary:
11 Buy, 13 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
11 Buy, 13 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
BMO Capital analyst George Farmer raised the price target on Editas Medicine (NASDAQ: EDIT) to $40.00 (from $28.00) while maintaining a Outperform rating.
- $225K/year price tag of newly FDA-approved Vyndaquel and Vyndamax (tafamidis; Pfizer) for treatment ATTR-cardiomyopathy (ATTR-CM).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- Honasa Consumer Ltd (HONASA:IN) PT Raised to INR720 at ICICI Securities
- GMR Airports Infrastructure (GMRI:IN) PT Raised to INR99 at ICICI Securities
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
BMO Capital, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
